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Rat lungworm (Angiostrongylus cantonensis) is a neurotropic nematode, and the leading cause of eosinophilic
meningitis worldwide. The parasite is usually contracted through ingestion of infected gastropods, often hidden
in raw or partially cooked produce. Pharmaceutical grade pyrantel pamoate was evaluated as a post-exposure
prophylactic against A. cantonensis. Pyrantel pamoate is readily available over-the-counter in most pharmacies
in the USA and possesses anthelmintic activity exclusive to the gastrointestinal tract (GIT). Administering pyr
antel pamoate immediately after exposure should theoretically paralyze the larvae in the GIT, causing the larvae
to be expelled via peristalsis without entering the systemic circulation. In this study, pyrantel pamoate (11 mg/
kg) was orally administered to experimentally infected rats at 0, 2-, 4-, 6-, or 8-h post-infection. The rats were
euthanized six weeks post-infection, and worm burden was evaluated from the heart-lung complex. This is the
first in vivo study to evaluate its efficacy against A. cantonensis. This study demonstrates that pyrantel pamoate
can significantly reduce worm burden by 53–72% (P = 0.004), and thus likely reduce the severity of infection
that is known to be associated with worm burden. This paralyzing effect of pyrantel pamoate on the parasite may
also be beneficial for delaying the establishment of infection until a more suitable anthelmintic such as alben
dazole is made available to the patient.

1. Introduction
Angiostrongylus cantonensis is an obligate, digenetic, parasitic nema
tode and the causative agent for the clinical condition known as neu
roangiostrongyliasis (rat lungworm disease) that often results in
eosinophilic meningitis. The first human neuroangiostrongyliasis case
was reported from Taiwan in 1945 (Nomura and Lin, 1945), and ac
cording to various reports, the parasite has been spreading throughout
Asia, the Caribbean, Africa, South America, and the Pacific, including
Hawaii (USA) (Wang et al., 2008; Jarvi et al., 2017). Recently
A. cantonensis has also been detected in other states in the USA,
including Florida, Louisiana, Texas, Oklahoma, Tennessee, and South
Carolina (Kim et al., 2002; Stockdale Walden et al., 2017; Teem et al.,
2013; Underwood et al., 2019). Additionally, autochthonous human
cases have been reported from several states including Texas, and

Tennessee (Flerlage et al., 2017; Foster et al., 2016), and also in Europe
(Nguyen et al., 2017). The State of Hawaii is considered a hotspot for
neuroangiostrongyliasis in the USA, with over 82 reported cases be
tween 2007 and 2017 (Johnston et al., 2019). Infections are mainly
caused by accidental ingestion of third stage larvae (L3) from infected
mollusks, typically hidden in produce. The severity of the disease can
range from mild symptoms to serious life-long neurological anomalies,
paralysis, and even death (Wang et al., 2008). This dramatic range of
symptoms is thought to be correlated with the number of parasites
involved in the infection, with higher worm burdens causing more se
vere symptoms (Ji et al., 2017; Wang et al., 2008). Currently, in the USA,
specific treatments are only initiated after diagnostic confirmation by
detecting A. cantonensis DNA in the cerebrospinal fluid (Ansdell et al.,
2021; Qvarnstrom et al., 2016).
Pyrantel pamoate is an FDA-approved, over-the-counter (OTC)
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anthelmintic that showed significant in vitro efficacy against
A. cantonensis L3s in our previous studies (Jacob et al., 2021b). Pyrantel
pamoate is commonly used for pinworms (Enterobius vermicularis) as
well as for lungworms, filariae, and arthropods (Martin and Geary,
2016; Pickering et al., 2006). The significant activity shown by pyrantel
pamoate against A. cantonensis in vitro, and its availability as a safe OTC
drug with anthelmintic activity exclusive to the gastrointestinal tract
(GIT) made its candidacy as a potential post-exposure prophylactic
(Jacob et al., 2021b). In theory, administering pyrantel pamoate
immediately after a known ingestion of rat lungworm is expected to
paralyze the larvae in the GIT, allowing the larvae to be expelled via
peristalsis without entry into the systemic circulation.
Based on the results from our previous in vitro study (Jacob et al.,
2021b), Hilo Medical Center hospital, in Hawaii, has added pyrantel
pamoate to their treatment guidelines as a prophylactic after a known
exposure (Hilo Medical Center, 2020). According to these guidelines, the
first-line response after a known exposure is to induce emesis as soon as
possible, then obtain pyrantel pamoate from the nearest pharmacy and
administer it according to the manufacturer’s instructions, followed by
care from the primary care provider. Other in vitro studies have also
suggested pyrantel to be a good candidate by evaluating the motility
patterns of adult worms, post-exposure (Mentz and Graeff-teixeira,
2003; Terada et al., 1983, 1982; Terada and Sano, 1986). Addition
ally, Lämmler and Weidner (1975), investigated the efficacy of pyrantel
against A. cantonensis, albeit in its tartrate form, in multimammate rats.
In their study, pyrantel tartrate (200 mg/kg) was administered from the
fifth day post-infection for five consecutive days and showed 60.6%
reduction of worm burden. Pyrantel tartrate is more hydrophilic than its
pamoate form, allowing the pyrantel to be systemically absorbed.
Hence, pyrantel tartrate would continue to exert its effects even after
A. cantonensis larvae have entered the circulatory system (Martin and
Geary, 2016). However, this superior systemic absorption of pyrantel
tartrate is also associated with significant toxicity in humans (PubChem
Pyrantel, 2021) and thus its use is limited to veterinary applications
(Nielsen, 2015). Hence, formulations of pyrantel intended for human
use attach a pamoate moiety, making the molecule highly lipophilic,
thereby minimizing systemic absorption from the GIT and associated
toxicity. This study is the first in vivo investigation of the efficacy of
pyrantel pamoate against A. cantonensis.

2.3. Larval (L3) isolation
Semi-slugs (Parmarion martensi) were collected from the east region
of Hawaii Island, and L3s were isolated as previously described Jarvi
et al. (2019). Briefly, approximately 50 semi-slugs were individually
drowned in 50 ml Falcon tubes filled with tap water for 72 h, after which
slugs were removed, and the bottom 10 ml of water (containing larvae)
from each of the tubes was collected into separate culture plates (100
mm × 15 mm). Larvae were isolated under a dissecting microscope
(Leica S9 D and Wild Heerbrugg M4A APO) and pooled into a single
separate culture plate containing dH2O, using a 20 μl micropipette.
These larvae (n = 50) were then handpicked and transferred into
separate 1.5 ml Eppendorf tubes containing 500 μl of dH2O (n = 36
tubes), which was later used for gavage. All animal procedures were
conducted in accordance with the approved protocols (see ethical
standards).
2.4. Experimental infection
Rats in the infected control group and the hourly treatment groups
(n = 36 rats) were gavaged with 50 larvae each, in 500 μl of dH2O, into
the distal esophagus, using sterile flexible plastic gavage tubes (Instech
Laboratories, Inc., Plymouth Meeting, PA, USA) and 1 ml sterile tuber
culin syringes (Norm-ject, Tuttlingen, Germany). Similarly, rats in the
untreated control and pyrantel control groups (n = 12) were gavaged
with 500 μl of dH2O without larvae. All rats were sedated prior to the
gavage with a mixture of isoflurane – oxygen gas using a Tec III 300P
vaporizer (Vaporizer Sales & Services, Rockmart GA, USA) placed
within a DWS36-A ductless fume hood (Air Science DWS Downflow
Workstation, Fort Myers, FL, USA).
2.5. Pyrantel treatment

Wistar rats (Rattus norvegicus) IGC outbred strain (Code 003) were
purchased from Charles River Labs (Raleigh, NC, USA). All rats were
immediately weighed upon arrival, individual animals were identified
with a cage card with animal number IDs, and each was housed in a
polycarbonate shoebox cage (21 × 47 × 26 cm) at the USDA APHIS
Wildlife Services National Wildlife Research Center (NWRC) Hawaii
Field Station, Hilo, HI, USA. Rats were between 8 and 9 weeks of age at
the beginning of the study. Rats were maintained on Laboratory Rodent
Diet 5001 (LabDiet, St. Louis, MO, USA) and provided both food and
water ad libitum. Rats were allowed to acclimate for a minimum 7–10
days before initiating the study.

Pharmaceutical grade pyrantel pamoate (Reese’s pinworm medicine,
Cleveland, OH, USA) was used in this study. The typical dosage of
pyrantel pamoate for humans is 11 mg/kg, with dosing determined by
the amount of pyrantel base (Papich, 2016). Pharmaceutical grade
pyrantel pamoate contains 50 mg/ml pyrantel base, a high dose to be
directly used in rats due to their smaller body weight. Therefore, we
reformulated the pharmaceutical product to contain the required dose of
pyrantel (11 mg/kg) in a volume of 500 μl dH2O for gastric gavaging in
rats. The average body weight of male and female rats was calculated,
and 11 mg/kg unit doses were formulated accordingly for both sexes,
using dH2O, making the final volume of 500 μl per 1.5 ml Eppendorf
tube.
All the rats in the pyrantel control group and the hourly treatment
groups (n = 36 rats) were gavaged with this pyrantel formulation based
on the weight of the rats. For the hourly treatment groups, pyrantel
formulation was gavaged according to the respective treatment group,
that is, 0, 2-, 4-, 6- and 8-h PI. Similarly, rats from the untreated and
infection control groups (n = 12) were gavaged with 500 μl of dH2O. The
pyrantel formulation was also gavaged in the same manner as the larvae,
as described above. All rats were sedated prior to gavaging.

2.2. Study design

2.6. Necropsy

A total of 48 rats were used in this study, equally divided into 8 study
groups with 6 rats in each group. The study groups consisted of: (1)
untreated control (2) infected control; (3) pyrantel pamoate (unin
fected) control; with pyrantel administration at different time points
post-infection (PI): (4) 0-h (immediately after infection); (5) 2-h PI; (6)
4-h PI; (7) 6-h PI; and (8) 8-h PI. Each group consisted of an equal
number of male and female rats.

Rats were held for 6 weeks post-infection and humanely euthanized
in a CO2 chamber. The heart-lung complex was dissected and placed into
individual culture plates and was examined using fine-tip forceps under
a Leica 10–40X dissecting microscope for the presence of adult worms.
The number of worms recovered from each rat was recorded. One worm
from each rat was used for the confirmation of A. cantonensis using PCR
(Sears et al., 2021).

2. Materials and methods
2.1. Animal care
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2.7. Statistical analysis

Table 1
Summary of worms recovered from heart-lung complex of experimentally
infected rats. Groups include a no-drug control, and treatments with pyrantel
pamoate (11 mg/kg) at 0 h (immediate), 2-h, 4-h, 6-h, and 8-h post-L3 exposure.

After testing for heteroscedasticity, one-way ANOVA was used to
evaluate the number of worms extracted post-infection across study
groups. The worm burden after no drug treatment and pyrantel pamoate
treatment (all hourly treatment groups combined) was analyzed using
orthogonal contrasts. Tukey’s test was used to determine the signifi
cance of worms recovered over time. A two-way ANOVA was used to
examine the effect of sex of the rat on the number of worms extracted
after hourly treatments. All statistical analyses were performed using
Minitab (Minitab, LLC., State College, PA) software, version 18.0. Level
of significance for all analyses was set at an alpha equal to 0.05.
3. Results
3.1. Worm recovery
A total of 252 adult worms were recovered in this study and were
genetically identified as A. cantonensis using PCR (Sears et al., 2021).
The mean of the number of worms recovered from the no drug control
group and each hourly treatment group, along with their standard de
viations (SD) were used to plot a time-response curve (Fig. 1). The red
dotted trend line represents the time-dependent, post-exposure pro
phylactic activity of pyrantel pamoate against A. cantonensis (P =
0.004). There was a significant difference in the overall mean number of
worms recovered between the no drug control group (13.83 ± 3.49 SD)
and all the pyrantel pamoate hourly treatment groups (5.63 ± 4.81 SD)
(P = 0.0004), with a reduction of 53% in the number of worms recov
ered from 0-h treatment group as compared to the infected control
group, where the drug was administered immediately after gavaging the
infective larvae.
The mean number of worms recovered from the heart-lung complex
from each of the treatment group post-euthanasia, standard deviations
and their ranges within each group are shown in Table 1. In the 2-h
treatment group, the range for most of the rats (n = 5) was 2–12
worms, however, there was a single outlier with 24 worms recovered,
resulting in a large standard deviation (Table 1, Fig. 1). The dotted blue
line in Fig. 1 represents the mean worm recovery excluding the outlier
with 24 worms (n = 5 rats). The means and ranges for the 4-, 6-, and 8-h
groups were relatively consistent with means of 4.0, 4.17, and 4.0 and
ranges of 0–10, 2–8, and 1–10 worms recovered, respectively. Thus,
pyrantel pamoate was most effective when administered at 4, 6 and 8-h
post-infection (P=0.009, P=0.010, and P = 0.009, respectively). There
was no significance correlation between the sex of the rat and worm

Study group

Mean number of
worms recovered

Standard
deviations

Range of worms
recovered

No drug (n¼6)
0-h treatment
(n¼6)
2-h treatment
(n¼6)
2-h treatment
(n¼5)a
4-h treatment
(n¼6)
6-h treatment
(n¼6)
8-h treatment
(n¼6)

13.83
7.33

3.49
1.75

9–19
5–10

8.67

8.38

2–24

5.6

4.15

2–12

4.0

4.38

0–10

4.17

2.4

2–8

4.0

3.52

1–10

a

Excluding the outlier with 24 worms.

recovery (P = 0.72).
4. Discussion
The World Health Organization’s list of essential medicines consists
of those medications considered to be most effective and safe to meet the
most important needs in a health system (World Health Organization,
2021). Pyrantel pamoate has been included in this list as an anthelmintic
since 1983. In the US, pyrantel pamoate suspension formulations are
available (OTC) in most pharmacies. Pyrantel is a cholinergic agonist,
which binds to the nicotinic receptors at the neuromuscular junction
(NMJ). Such binding initiates the influx of cations, causing depolariza
tion of muscles, ultimately resulting in the spastic paralysis of parasitic
nematodes (Martin and Geary, 2016). Although pyrantel does not
directly kill the intestinal parasites, due to the induced paralysis they are
anticipated to then be expelled out of the body via peristalsis (Saari
et al., 2019).
Pyrantel pamoate’s potential as an early intervention complements
the use of albendazole, currently considered as the most suitable
anthelmintic for the management of neuroangiostrongyliasis. Albenda
zole has a broad spectrum of nematocidal activity, and it is the only
approved nematicide capable of crossing the blood-brain barrier (Jacob
et al., 2021a; Ramírez et al., 2001). Nonetheless, it has some significant
disadvantages. Albendazole is one of the most expensive drugs on the US
Fig. 1. Time-response curve representing
post-exposure prophylactic activity of pyr
antel pamoate against A. cantonensis. The
red trend line represents the time-dependent
activity of pyrantel pamoate. In the 2-h
treatment, the mean number of worms
recovered is calculated inclusive of the out
liers with 24 worms (n = 6), as well as
excluding this outlier (n = 5) with the
change in the time-response curve repre
sented by the dotted blue line.
** Statistical significance as compared to the
(no drug) controls (P < 0.005). (For inter
pretation of the references to colour in this
figure legend, the reader is referred to the
Web version of this article.)
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market and requires a clinical prescription (Shahriar and Alpern, 2020).
As previously discussed, in the US treatments specific to neuro
angiostrongyliasis are initiated only after diagnostic confirmation, even
for episodes of known exposure (Ansdell et al., 2021; Qvarnstrom et al.,
2016). During this time, the parasite will likely have already migrated to
the brain and caused neurological damage. Thus, there is a great need
for an affordable and more immediately available anthelmintic to pre
vent or minimize the severity of infection.
This study shows that pyrantel pamoate can significantly reduce
worm burden if administered early after exposure (P = 0.0004). The
severity of symptoms is thought to be correlated with the number of
parasites involved in the infection (Ji et al., 2017; Wang et al., 2008).
The ability of pyrantel pamoate to reduce the number of worms involved
in the infection, particularly if administered hours after a known expo
sure, has the potential to reduce the severity of symptoms. However,
unlike intestinal nematodes for which pyrantel pamoate is intended,
A. cantonensis larvae will attempt to enter the systemic circulation hours
after ingestion. According to Mackerras and Sandars (1955),
A. cantonensis larvae were detected in the blood by the fourth hour
post-infection in experimentally infected rats. Therefore, the timing of
pyrantel pamoate administration is very critical in the case of
A. cantonensis exposure. However, in humans, for larvae to enter the
bloodstream may be delayed considering the greater volume and asso
ciated surface area of the human GIT, as compared with the rat GIT.
Angiostrongylus costaricensis is also a digenetic parasitic nematode
with a lifecycle very similar to that of A. cantonensis. However,
A. costaricensis is not a neurotropic parasite but an intestinal parasite and
the causative agent of the clinical condition known as abdominal
angiostrongyliasis. Although A. costaricensis is a different species, pyr
antel pamoate may also be beneficial for the management of abdominal
angiostrongyliasis. Previous in vitro studies that investigated pyrantel’s
efficacy against A. costaricensis based on motility and egg development
have reported it to be effective (Ishih et al., 2001; Mentz and
Graeff-teixeira, 2003; Terada et al., 1986).
Our study shows that post-exposure administration of pyrantel
pamoate significantly reduces A. cantonensis worm burden, however,
our results seem counter-intuitive with a longer delay in the adminis
tration of pyrantel pamoate resulting in a greater reduction in worm
burden (i.e., 0- and 2-h post-exposure vs. 4-, 6- and 8-h post-exposure).
To explain such results, it must be reiterated that pyrantel pamoate will
only impart its anthelmintic activity while remaining in contact with
A. cantonensis larvae (Jacob et al., 2021b). Thus, we believe the trend
line in Fig. 1 illustrates the effects of various GI events on the duration of
pyrantel pamoate retention within the GIT and the reduction in worm
burden as a result. Several factors could affect the duration of contact
between pyrantel pamoate and A. cantonensis larvae, such as food/liquid
contents and the co-location of the larvae in the GIT at the time of
pyrantel administration. Additionally, the viscosity of pyrantel prepa
ration, gastric emptying time, and peristalsis are also factors that may
influence the duration of contact between the larvae and pyrantel
pamoate.
In this study, rats were neither deprived of food or water prior to the
administration of pyrantel pamoate, as to mimic the real-life scenario of
accidental exposure. The rats involved in this study were continuously
provided with food and water ad libitum. The amount of food could delay
or even prevent the uniform distribution of pyrantel within the stomach,
allowing a few A. cantonensis larvae to migrate into the circulation.
Similarly, large volumes of liquid in the stomach could dilute pyrantel,
retarding its anthelmintic activity or making it ineffective. These factors
may offer an explanation for the variation in the number of worms
recovered from individual rats within the same treatment group, such as
the outlier in the 2-h treatment, resulting in large standard deviations
(Table 1, Fig. 1).
Perhaps most critically, the gastric emptying time for solid meals in
rats is approximately 1 h (Purdon and Bass, 1973) while that for liquids
is more immediate (Bennink et al., 2003). When administering

pharmaceutical grade pyrantel pamoate, its high viscosity (due to sol
vents used such as glycerin), results in having an extended duration of
contact with the larvae in the stomach. However, in this study, the
necessary reformulation of pyrantel pamoate using dH2O considerably
reduced its viscosity. Considering this, it is possible that during the more
immediate post-exposure hours of treatment (0–2 h), the reformulated
pyrantel may have been more rapidly flushed down into the smaller
intestine, with a minimum duration of contact with the larvae situated in
the stomach, where the majority would be expected to be at this point in
time.
However, by the 4th-hour post-exposure, though few larvae might
have already made entry into the circulation (Mackerras and Sandars,
1955) (the plateau with an average of 4 worms seen from the 4th-hour
treatment in Fig. 1, Table 1), the majority would have moved to the
small intestine along with the food contents. The less viscous pyrantel
pamoate administered during this 4th hour period is likely to have
rapidly passed into the small intestine, putting the majority of the larvae
in contact with the drug. Furthermore, peristaltic motion should evenly
distribute pyrantel pamoate within the intestine, providing more chance
of contact with these larvae for an extended duration. However, this may
not be the case when the original (undiluted) pharmaceutical grade
pyrantel pamoate is used. Due to its high viscosity, it is expected that the
retention time in the stomach and the duration of contact with larvae
will both be greater during the early hours post-ingestion, providing
minimal opportunities for these larvae to make entry into the
circulation.
This study clearly demonstrates a significant reduction in the number
of adult worms recovered after treatment with pyrantel pamoate in rats.
However, additional studies are required to establish clinical relevance
for this post-exposure prophylactic in humans.
5. Conclusion
Though the administration of pyrantel pamoate significantly reduced
the number of A. cantonensis, our results made it clear that further
investigation into the timing of administration of pyrantel pamoate is
needed, given the limited period for the ingested larvae and pyrantel
pamoate to co-locate within the same GI compartment. The postexposure prophylactic efficacy of pyrantel pamoate when reformu
lated in a more viscous solvent such as glycerin or liquid paraffin may
also impact results. Our research clearly shows that post-exposure
administration of pyrantel pamoate can reduce the worm burden
under this condition, with a potential reduction in severity of infection.
Furthermore, the paralyzing effects of OTC pyrantel pamoate may also
delay the establishment of infection until a more suitable anthelmintic
such as albendazole is made available to the patient.
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